Meeting
2020 Genitourinary Cancers Symposium
Late toxicity and quality of life from GETUG-AFU 22 study.
Authors
Igor Latorzeff
Clinique Pasteur, Toulouse, France
Igor Latorzeff , Stephane Guerif , Sandra Pelissier , Emmanuel Meyer , Julien Fraisse , Stephane Supiot , Gilles Crehange , Edouard Lagneau , Philippe Ronchin , Ahmed Benyoucef , Ali Hasbini , Pascal Pommier , Guy De Laroche , Laurent Salomon , Paul Sargos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01994239
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 331)
Abstract #
331
Poster Bd #
M15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel
Poster
2013 Genitourinary Cancers Symposium
Long-term health-related quality of life in patients treated for localized prostate cancer.
First Author: Sanoj Punnen
Poster
2024 ASCO Genitourinary Cancers Symposium
Pretreatment colonoscopy impact on acute gastrointestinal (GI) toxicity following curative stereotactic body radiation therapy (SBRT) for localized prostate cancer.
First Author: Jonathan W. Lischalk
Poster
2023 ASCO Genitourinary Cancers Symposium
Urinary proteome as a prognostic factor in the deterioration of the quality of life of patients with localized prostate cancer during radiotherapy: Radiotoxicity Bladder Biomarkers (RABBIO) prospective trial.
First Author: Carole Helissey